EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Strata Critical Medical, Inc. (SRTA) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Strata Critical Medical, Inc. $0.92, price $4.73, upside -80.6%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US0926671043

SC Strata Critical Medical, Inc. logo Thin data Sep 24, 2026

Strata Critical Medical, Inc.

SRTA · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.9200 · Strongly overvalued (−80.6%)
!Quality 44/100
!Expensive Growth (revenue 5y +53.1 %/yr)
✓Highly profitable · 20.6% net margin (TTM)
!negative free cash flow
!Trails peers (3/9)
!Narrow moat 25/100
!Evidence only low, so the estimate is less certain
Watch Strata Critical Medical, Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$11.63 $2.08 Fair Value $0.9200 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $2.08 – $11.63 · fair‑value band $0.6100 – $1.15 · the $4.73 price screens above the $0.9200 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Strata Critical Medical in your weekly email

Every Wednesday you see whether Strata Critical Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical.

Show more

Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical. The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services. It also provides other clinical services comprising cardiac perfusion services, blood management and autotransfusion services, extracorporeal membrane oxygenation services, perfusion staffing, and equipment rentals. The company was formerly known as Blade Air Mobility, Inc. and changed its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.

Stock analysis

Strata Critical Medical, Inc. (SRTA) currently trades at $4.73, while our model-based Fair Value estimate is $0.9200, 80.6% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.6100 (bear) to $1.15 (bull), the price of $4.73 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Strata Critical Medical, Inc. reported revenue of $197M in FY2025 versus $50.5M in FY2021, a compound +40.5%/yr. Reported net income was −$15.6M in FY2025.

Key figures

Market cap $491M · P/S ratio 2.15 · EPS (TTM) $−0.1900 · Net margin −7.9% · Return on equity −6.4% · Return on assets (EBIT) −12.6% · Operating margin −2.8% · Revenue (TTM) $229M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 27% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −81%, SRTA screens richer than that median.

Fair Value models

Bear $0.6100 Fair Value $0.9200 Bull $1.15
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $1.61 $2.16 $3.23 51
All 1 models by family
Asset-Based
NCAV (Graham) $1.61 $2.16 $3.23 51

Open the full fair value analysis →

Notify me when SRTA reaches fair value

Put SRTA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 44/100

Of which business quality 45 · Market factors (momentum, volatility) 27

Profitability 12
Margins and returns on capital today
Quality Growth 36
Are margins and returns improving?
Cashflow 33
Earnings quality: real cash, not paper profit
Fin. Strength 83
Balance sheet, leverage, solvency risk
Investment 92
Disciplined investing over empire-building
Low Volatility 4
Calm price path (market factor)
Momentum 42
Price trend over the last 3–12 months (market factor)
52W Momentum 27
Distance to the 52-week high (market factor)
Net Issuance 24
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−20.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+53.1%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−44.2% (2020) → −5.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SRTA screens overvalued: fair value 81% below the price. Compare with HCA Healthcare, Inc →

Compare Strata Critical Medical, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 241 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 45 · Bottom 25%
Fair Value upside −81.0% · Bottom 25%
Profitability
Return on assets −1.9% · Bottom 25%
Net margin (TTM) 20.6% · Top 25%
Operating margin (TTM) −2.8% · Bottom 25%
Growth and dividend
Revenue growth 87.4% · Top 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 1.76× · Cheaper than median
P/S (TTM) 2.15× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 33
FUTURE (revenue growth)100 · sector 29
PAST (return on equity)0 · sector 32
HEALTH (low debt)0 · sector 89
DIVIDEND (yield)0 · sector 38

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $431.63 $597.97 +39%
Fresenius SE FRE €43.64 €34.49 −21%
Dr. Sulaiman Al Habib Medical Services Group 4013 225.00 SAR 109.45 SAR −51%
Tenet Healthcare Corporation THC $257.93 $274.35 +6%
IHH Healthcare Berhad, an investment holding company, 5225 8.03 MYR 4.87 MYR −39%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,889 ₹2,908 −67%
Encompass Health Corporation EHC $123.47 $94.47 −23%
Fresenius Medical Care AG FMS $22.27 $45.84 +106%
DaVita Inc DVA $178.07 $215.81 +21%
Aier Eye Hospital Group 300015 ¥7.91 ¥10.86 +37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Strata Critical Medical, Inc. · Fair Value
$0.9200 −81%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Strata Critical Medical, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/SRTA

Frequently asked questions

Is Strata Critical Medical, Inc. (SRTA) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.9200 versus a price of $4.73, about −81% upside (overvalued).
What is the fair value of SRTA?
Our model-based fair value for Strata Critical Medical, Inc. is $0.9200 (as of Sep 24, 2026), built from audited fundamentals. The current price: $4.73.
What is the quality score of SRTA?
Strata Critical Medical, Inc. has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Strata Critical Medical, Inc. (SRTA)?
Our model-based price target is the fair value of $0.9200 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.6100, optimistic scenario $1.15. It is a calculation from audited fundamentals, not an analyst target.
What is the Strata Critical Medical, Inc. stock forecast for 2026?
Our models put fair value at $0.9200, about −81% upside versus a price of $4.73 (overvalued). Cautious scenario $0.6100, optimistic scenario $1.15. The calculation is refreshed regularly with new filings.
What is the revenue of Strata Critical Medical, Inc. (SRTA)?
Strata Critical Medical, Inc. reported trailing-twelve-month revenue of about $229M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Strata Critical Medical, Inc. (SRTA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Strata Critical Medical, Inc. it is $0.9200 per share (as of Sep 24, 2026), against a price of $4.73. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Strata Critical Medical, Inc. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, SRTA trades above its calculated fair value: price $4.73, fair value $0.9200, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SRTA?
No. The price is what the market pays today ($4.73); the fair value is what the company's own numbers justify ($0.9200). For Strata Critical Medical, Inc. the two are $3.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is Strata Critical Medical, Inc. worth?
The market values Strata Critical Medical, Inc. at about $491M (market capitalisation, as of Sep 24, 2026). Per share that is $4.73; our models calculate a fair value of $0.9200 per share.
What do the bullish and bearish scenarios say about SRTA?
Our models span a range for Strata Critical Medical, Inc.: cautious scenario $0.6100, base $0.9200, optimistic $1.15 per share (as of Sep 24, 2026, price $4.73). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Strata Critical Medical, Inc. (SRTA)?
Balance-sheet figures for Strata Critical Medical, Inc. (as of Sep 24, 2026): return on equity −6.4%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is SRTA from its 52-week high?
Strata Critical Medical, Inc. trades at $4.73, about 27% below its 52-week high of $6.47 and 17% above the low of $4.03 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.9200 is for.
Which stocks are comparable to Strata Critical Medical, Inc.?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Strata Critical Medical, Inc. stock attractive at the current price?
The data as of Sep 24, 2026: price $4.73, calculated fair value $0.9200 (−81%), Quality Score 44/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SRTA calculated?
We run Strata Critical Medical, Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.9200, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Strata Critical Medical, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Strata Critical Medical, Inc. (SRTA)?
The closing price on Oct 2, 2026 was $4.73. Our model-based fair value is $0.9200, about −81% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Strata Critical Medical, Inc. right now?
The price sits above even our optimistic bull case ($1.15). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.6100 to $1.15) leaves room in how you read the outcome.

Key figures of Strata Critical Medical, Inc.

How large is the market capitalisation of Strata Critical Medical, Inc. (SRTA)?
The market capitalisation of Strata Critical Medical, Inc. is $491M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Strata Critical Medical, Inc. (SRTA)?
The price-to-sales ratio of Strata Critical Medical, Inc. is 2.15 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Strata Critical Medical, Inc. (SRTA)?
Earnings per share at Strata Critical Medical, Inc. are $−0.1900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Strata Critical Medical, Inc. (SRTA)?
The net margin of Strata Critical Medical, Inc. is −7.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Strata Critical Medical, Inc. (SRTA)?
The return on equity (ROE) of Strata Critical Medical, Inc. is −6.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Strata Critical Medical, Inc. (SRTA)?
On an EBIT basis the return on assets of Strata Critical Medical, Inc. is −12.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Strata Critical Medical, Inc. (SRTA)?
The operating margin of Strata Critical Medical, Inc. is −2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Strata Critical Medical, Inc. (SRTA)?
Revenue at Strata Critical Medical, Inc. is growing +87.4% versus a year earlier (3y avg +10.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Strata Critical Medical, Inc. (SRTA) generate?
The free cash flow of Strata Critical Medical, Inc. is −$59.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Strata Critical Medical, Inc. (SRTA) hold?
Strata Critical Medical, Inc. holds more cash than debt, $27.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Strata Critical Medical, Inc. in the live analysis

One click puts Strata Critical Medical, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.